ICER Boosts ‘Cost-Recovery’ Benchmark Price For Remdesivir To Reflect Gilead’s Planned R&D
But updated pricing model also suggests the more traditional ‘cost effectiveness’ benchmark price for remdesivir could be lower than previously estimated to account for use of dexamethasone in reducing the underlying risk of mortality in COVID-19 patients.
You may also be interested in...
Coronavirus Update: Spooked By America’s COVID-19 Vaccine Skepticism, FDA Promises Not To Lower Standards
The FDA has released detailed guidance to COVID-19 vaccine manufacturers setting out the safety and efficacy standards required, and pledged to not cut corners.
Highly anticipated decision bodes well for pricing of other future treatments for the disease, the US Institute for Clinical and Economic Review suggests.
Independent drug cost watchdog updates its twin pricing estimates for Gilead's drug - but dexamethasone could tip the balance again.